

# Index

- acetylcholinesterase inhibitors 106
- action potentials  
 saltatory conduction 8, 29, 67  
 sodium channel activity and 37–9  
 transmission in demyelinated axons 29–30
- adaptation, rehabilitation and 153
- adenosine triphosphate (ATP) levels 31
- aerobic training 145, 153
- airway protection 219
- alpha blockers 4
- amantadine 187
- 4-aminopyridine 114
- amitriptyline 187
- AMPA receptor antagonists 24
- anesthetics, local 33
- anisotropy 80
- antidepressant drugs 146, 185, 187
- antimuscarinic agents 192
- antipsychotic drugs 186
- antispasticity drugs 168–71, 172
- anxiety 184
- apparent diffusion coefficient (ADC) 80
- aquatic therapy 146
- arteriovenous malformation (AVM)  
 pre-surgical mapping 106–8
- Ashworth Scale 132, 166–7
- aspiration 220, 223, 227
- astrocytes  
 CNS precursor differentiation determination and 74  
 oligodendrocyte precursor cells (OPCs) and 53, 55–6  
 remyelination role of 55  
 Schwann cell (SC) interaction 69, 70
- ataxia and imbalance
- as cognitive and metabolic impairment 211–12
- decomposing sensory–motor disturbance 205–6
- diagnosis of 203
- future research directions 212
- individual training program for 209–11
- muscle chaining in voluntary and involuntary actions 203–5
- paroxysmal attacks 37
- pathophysiology 201–2
- postural training principles and rationale 207–8
- rehabilitation conceptual framework 203
- sodium channel blocker use 40
- specificity in MS 202
- terminology of 201
- atrophy  
 CIS and early RRMS findings 10  
 cognitive rehabilitation studies 181  
 gray matter imaging 88–9  
 spinal cord 10, 14  
 white matter measurement 79, 80
- atropine, intravesical 3
- attention 177–8
- axonal assay, in vivo techniques 25–7
- axonal damage/degeneration/loss  
 axonal die-back 46  
 calcium-mediated injury 30, 31, 32  
 diffuse white and gray matter damage and 13–16  
 energy insufficiency and sodium influx 31  
 excitotoxicity and 24–5  
 inflammation and 9, 10  
 lesion-related 9–13, 16  
 mechanisms in traumatic injury and MS 45  
 secondary degeneration in inactive lesions 13  
 sodium channels as therapeutic targets 30–1
- axonal regeneration 13, 45–8
- azathioprine 114
- baclofen 168, 169, 172  
 intrathecal (ITB) 169, 170–1, 172
- balance disturbances *see* ataxia and imbalance
- Balance Master 210–11
- bands of Bügner 68
- Barthel Index (BI) 132
- basal lamina (BL) 61
- B cells 16
- Beck Fast Screen for Depression in Medically Ill Patients 184
- benzodiazepines 169, 186
- beta-amyloid precursor protein ( $\beta$ -APP) 32, 33
- bipolar disorder 185–6
- bladder dysfunction  
 antimuscarinic medication use 192  
 botulinum toxin use 197–8  
 cannabinoid use 196  
 clean intermittent self-catheterization (CISC) 192–5  
 DDAVP 194  
 long-term indwelling catheter use 197–8  
 management of incomplete emptying 193  
 mood stabilizing drugs and 186  
 pelvic floor training 146  
 sexual dysfunction and 216  
 urological damage risk 194–5
- blood–brain barrier (BBB)  
 increased permeability of 44  
 magnetic resonance imaging (MRI) and 79, 80, 83
- bone marrow, mesenchymal stem cells in 73
- bone morphogenetic protein (BMP) 53, 63, 68, 74

- botulinum toxin  
bladder dysfunction treatment 197  
spasticity treatment 169, 171, 172
- boundary cap cells (BC) 71
- bowel dysfunction, sexual dysfunction and 216
- brain-derived neurotrophic factor (BDNF) 70
- brain parenchymal fraction (BPF) 181
- brain tumor, pre-surgical mapping 106–8
- brainstem  
respiratory control 227  
swallowing control 220
- bromocriptine 217
- bulbar problems  
dysarthria 146, 219, 224–7  
dysphagia 146, 219–24  
future research directions 228  
interdependence of 219  
respiratory impairment 227–8
- bupropion 185
- Cajal, R. 60, 68
- calcium ions  
calcium-mediated axonal injury 30, 31, 32  
sodium–calcium exchanger (NCX) 30, 32  
synaptic plasticity 23
- cAMP-response-element-binding protein (CREB) 62
- Canadian Occupational Performance Measure (COPM) 130
- cannabinoids 170, 196
- capsaicin 196
- carbamazepine  
ataxia treatment 37  
bipolar disorder treatment 186  
dysesthesia treatment 217  
neuroprotective effect of 33, 34, 36  
paroxysmal pelvic pain treatment 215  
spasticity treatment 170
- carers  
dysphagia rehabilitation 223  
home-based care issues 232, 236  
quality of life 140
- Caspr (contactin-associated protein) 30, 32, 33
- CD45, 35, 36
- central conduction  
central motor conduction time (CMCT) 2, 4–5  
conduction block 5, 8, 44  
difficulties in failure assessment 3  
evoked potential (EP) studies, *see* evoked potentials (EPs)  
failure in MS 3–6  
pathophysiology in MS 2  
saltatory conduction 8, 29, 67
- central motor conduction time (CMCT) 2  
methylprednisolone treatment studies 4–5  
temperature vulnerability and 5
- cerebellar dysfunction  
ataxia and 36, 201–2  
dysphagia and 220  
sodium channel blockers and 40
- cerebellum, Na<sub>v</sub>1.8 in 36–40
- cerebral perfusion 83
- chest infections 146
- chlorpromazine 186
- Cho (choline-containing phospholipids) 81, 82, 88
- choking 223
- cholinesterase inhibitors 100
- chondroitin sulfate proteoglycan 53
- clinical nurse specialists, dysphagia management role 222
- clinical trials  
rehabilitation trial problems 152, 158–9, 176–7, 209  
source of error in RCTs 157–8  
UK Medical Research Council framework 161–2
- clinically isolated syndrome (CIS)  
imaging studies 9, 81, 95  
progressive brain atrophy in 10
- clinico-radiological paradox 79
- clonidine 169, 170
- Cofilin 47
- cognitive behavioral therapy (CBT) 146, 185
- cognitive impairment 176  
antimuscarinic medication use and 3  
ataxia and 212  
electrophysiological assessment of function 114–16  
fMRI studies 95–6
- cognitive rehabilitation  
assessment for 177  
attention training 177–8  
executive skills training 180  
memory training 178–80  
methodological difficulties in evaluation 176–7  
MRI findings 181  
patient evaluation of 180–1  
research findings 146–7, 161  
use of technology and aids 180
- communication  
augmentative and alternative communication (AAC) systems 227  
functional techniques 227  
speech disturbances, *see* dysarthria
- conduction block 5, 8, 44
- confocal microscope technology 25–7
- contactin-associated protein (Caspr) 30, 32, 33
- cooling therapy 146
- cortical reorganization  
*see also* neuroplasticity  
dislocation and relocation 107  
fMRI findings, *see* functional magnetic resonance imaging (fMRI)  
learning in the healthy brain 121  
longitudinal changes assessment 98  
rehabilitation mode of action and 143  
role of 98, 98  
structural MR damage and extent of 97
- creatine (Cr) 81, 82
- Cronbach's coefficient alpha 133
- cytokines, inflammatory 5
- dantrolene 169
- darifenacin 192
- DDAVP 194
- demyelination, functional effects of 8
- dendritic arborisation, increased 13
- depression  
anxiety and 184  
etiology of 184–5  
in caregivers 236  
major or subsyndromal 183  
prevalence of 183–4  
suicide 184, 185  
symptoms of 184  
treatment of 146, 185
- desire, sexual 215

## Index

- Detrusitol (tolterodine) 190
- detrusor overactivity (DO) 190–3, 195
- detrusor–sphincter dyssynergia (DSD) 190–3, 195
- dextromethorphan 187
- diagnosis  
   evoked potentials (EPs) use 1, 112–13  
   magnetic resonance imaging (MRI) use 1, 6, 79
- 3,4-diaminopyridine 100, 114, 123
- diaschisis 104, 106
- diazepam 169
- dietitian, dysphagia management role 222
- diffusion tensor (DT) tractography 82–3, 98
- diffusion tensor imaging (DTI)  
   diffuse white and gray matter damage studies 14–15  
   pre-surgical mapping 107  
   structural MR damage and functional cortical reorganization studies 97–8  
   white matter (WM) damage studies 80, 81–2
- disability  
   correlation with cMRI-visible lesions 79–80  
   lesion-related nervous damage and future 9  
   outcome measures 132
- disease activity  
   evoked potential (EP) studies 112–13  
   physical activity and 147
- disease progression  
   evoked potential (EP) studies 1–2, 113–14  
   therapeutic interventions and 140
- Dizziness Handicap Inventory short form (DHI<sub>sf</sub>) 211
- donepezil 106
- dorsal root ganglion, neural crest-derived stem cell (NCSC) in 72
- dysesthesiae 215, 217
- dysarthria  
   assessment of 225–6  
   features and classification of 224–5  
   incidence of 224  
   interdependence with respiration and swallowing 219  
   therapeutic interventions 146, 226–7
- dysarthrophonia 146
- dysphagia  
   airway protection 219  
   assessment of 221  
   clinical characteristics in MS 219, 220  
   incidence of 219  
   interdependence with speech and respiration 219  
   interdisciplinary team management approach 221–3  
   non-oral route feeding 224  
   pathophysiology 219–20  
   rehabilitation of 146, 223–4  
   symptoms of 220–1
- edema 5, 9
- ejaculatory problems 216
- electroconvulsive therapy (ECT) 185
- electroencephalography (EEG)  
   epilepsy use 108–9  
   magneto-EEG (MEG) 115  
   oscillatory activity investigations 115–16  
   simultaneous fMRI (SEM) 109
- emotional well-being, outcome measures 132
- employment issues 140
- Emselex (darifenacin) 192
- endocannabinoid neurotransmitter 166
- endosomal acidification 36
- endothelin 3, 73, 74
- endurance training 145
- energy conservation training 146
- energy insufficiency, axonal degeneration and 31
- Environmental Status Scale 132
- eperisone hydrochloride 169, 170
- ephrins 47
- epilepsy, fMRI use 108–9
- episodic ataxias 37
- Epstein–Barr virus 8
- equipment, provision of 145
- EquiScale questionnaire 211
- EquiTest 205–6, 209
- erectile dysfunction 216, 217
- euphoria 186–7
- event-related desynchronization (ERD)/synchronization (ERS) 116
- evoked potentials (EPs)  
   central conduction pathophysiology in MS 2  
   diagnostic use 1, 112–13  
   difficulties in central conduction failure assessment 3  
   disease activity assessment 112–13  
   disease progression 1–2, 113–14  
   event-related (ERPs) 115  
   prognostic use 1–2, 112  
   sexual dysfunction 216  
   treatment response measurement 113–14, 115  
   triple stimulation technique (TST) 3–6, 113
- excitatory post-synaptic potential (EPSP) 23
- executive function  
   atrophy and performance 89  
   cognitive rehabilitation and 180
- exercise interventions, in rehabilitation 144–6
- expanded disability status scale (EDSS)  
   evoked potential (EP) studies and 2  
   rehabilitation evaluation and 131
- experimental autoimmune encephalomyelitis (EAE)  
   confocal microscope studies 26  
   lesion location in 10  
   sodium channel studies 31–2, 33–5, 36, 37–40  
   synaptic and axonal changes 24
- external bladder stimulator 146
- fan rule, the 204–5
- fatigue  
   ataxia and 211–12  
   cortical reorganization and 98  
   drug-induced 122  
   dysphagia and 223  
   event-related desynchronization (ERD)/synchronization (ERS) and 116  
   evoked potentials (EPs) studies 114  
   outcome measures 132  
   thermosensitivity and motor fatigue 148
- Fatigue Impact Scale 132
- Fatigue Severity Scale 132
- fiberoptic endoscopic evaluation of swallowing (FEES) 221
- fibroblast growth factor (FGF) 53, 55
- financial issues 140, 148, 231  
   home-based care 232–3, 234, 235

- flecainide 33, 36
- fluorescence activated cell sorting (FACS) 56–7
- fluoxetine 106
- Functional Assessment Measure 132
- Functional Independence Measure 132
- functional magnetic resonance imaging (fMRI)
- blood oxygenation level dependent (BOLD) mechanism 93, 96
  - cognitive system investigations 95–6
  - epilepsy use 108–9
  - functional cortical reorganization and structural MR damage correlation 97–8
  - general considerations 93–4
  - learning in healthy brain 121–2
  - longitudinal changes of cortical reorganization assessment 98–100
  - longitudinal study design issues 120–1
  - motor system investigations 95
  - pre-surgical mapping 103, 106–8, 108–9
  - role of cortical reorganization studies 98
  - signal enhancement by extravascular protons (SEEP) effect 96
  - simultaneous EEG (SEM) 109
  - spinal cord investigations 96–7
  - stroke studies 103–6
  - therapeutic intervention monitoring 120–3
  - transcranial magnetic stimulation (TMS) combined with 123
  - visual system investigation 94
- GABA (gamma-aminobutyric acid) 166
- GABA receptors 168, 169
- gabapentin 169, 170
- galactorrhoea 171
- General Health Questionnaire 132
- glatirameracetate 140
- glial cells *see also* specific types
- gliogenesis 60, 61
  - increased activity of 82
- glial fibrillary acidic protein (GFAP) 61
- glutamate 23, 24–5
- glutamate–glutamine 88
- glycine 166
- Goal Attainment Scaling (GAS) 130
- gray matter (GM) damage
- atrophy 88–9
  - diffuse 13–16, 87–8
  - lesion imaging 86–7
  - pathological studies 86
  - spinal cord imaging 89
- gray matter fraction (GMF) 88
- green fluorescent proteins (GFP) 26
- group therapy 147
- Guy's Neurological Disability Scale 132
- haloperidol 186
- Hebb, D. 22
- heregulin 68
- hippotherapy 146
- home-based care 230, 232–6
- caregivers and 236
  - future objectives 236–7
  - MS Centers 231–2
- horse-riding therapy 146
- Hospital and Anxiety Depression Scale 184
- hydration
- dysphagia rehabilitation 223–4
  - non-oral route feeding 224
- hyperprolactinemia 217
- hypersexuality 215
- hypomania 185–6
- imbalance, *see* ataxia and imbalance
- immune modulation, *see also* specific immuno-modulatory therapies
- sodium channels and 35
  - therapies and disease progression 140
- incontinence, *see* bladder dysfunction
- inflammation
- axonal damage and 9, 10
  - early and late disease phase differences 11
  - neural stem/precursor cell (NPC) mediated repair and 62–4
  - reasons for lack of resolution 8
  - remyelination and 55
  - resolution of 12
- insulin-like growth factor 1 (IGF-1) 53, 55
- intention tremor 40, 201, 203
- interferon-beta
- disease progression and 140
  - drug-induced fatigue 122
  - evoked potentials (EPs) after 114, 115
- interleukin 6 (IL-6) 63
- International Classification of Functioning, Disability and Health (ICF) 128
- International Classification of Impairments, Disabilities, and Handicaps (ICIDH) 128
- intraclass correlation coefficient (ICC) 133
- intrathecal baclofen (ITB) 169, 171–172, 172
- involuntary emotional expression disorder/pseudobulbar affect (PBA) 187
- Item Response Theory (IRT) 135
- kainate (KA) 24
- kinases 47
- L'Hermitte's syndrome 224
- Lac (methyl resonance of lactate) 81, 82
- lamotrigine 33
- language function, pre-surgical mapping 106–8
- lateral geniculate nucleus (LGN) 94
- Lee Silverman Voice Treatment Programme (LSVT<sup>®</sup>) 227, 228
- lesion-related nervous damage
- gray matter imaging 86–7
  - lesion probability maps 15
  - physiopathology of 9–13, 16
  - white matter imaging 79–80
- levodopa 187
- lidocaine 33
- lifestyle changes 153
- lithium carbonate 186
- London Handicap Scale (LHS) 132
- long-term depression (LTD) 23–4, 48
- long-term potentiation (LTP) 13, 23–4, 48
- Lyrinel 4
- M.D. Anderson Dysphagia Inventory 221
- macrophages
- axonal transection and 9
  - glutamate release 24
  - remyelination role of 55
  - sodium channels and 35–6
- magnesium ions 23

## Index

- magnetic resonance imaging (MRI)  
 black holes 79, 80  
 cognitive rehabilitation  
 findings 181  
 diagnostic use 1, 6, 79  
 diffusion tensor (DT) tractography  
 82–3, 98  
 diffusion tensor imaging (DTI)  
*see* diffusion tensor imaging (DTI)  
 disorders of mood and affect studies  
 184, 186, 187  
 findings in clinically isolated  
 syndrome (CIS) and early  
 RRMS 9  
 functional (fMRI) *see* functional  
 magnetic resonance imaging  
 (fMRI)  
 gray matter (GM) damage studies  
 14, 86–9  
 magnetization transfer imaging  
 (MTI) *see* magnetization transfer  
 imaging (MTI)  
 perfusion 83  
 proton MR spectroscopy (<sup>1</sup>H-MRS)  
*see* proton MR spectroscopy  
 (<sup>1</sup>H-MRS)  
 secondary axonal degeneration  
 study 13  
 sexual dysfunction studies 216  
 structural MR damage and  
 functional cortical reorganization  
 correlation 97–8  
 suboptimal correlation with clinical  
 findings 93  
 white matter (WM) damage studies  
 14, 79–83
- magnetization transfer imaging (MTI)  
 clinically isolated syndrome (CIS)  
 findings 9  
 gray matter (GM) damage studies  
 14–15, 87, 89  
 lesion evolution studies 13  
 structural MR damage and  
 functional cortical reorganization  
 studies 97–8  
 white matter (WM) damage studies  
 14–15, 80, 81
- mania 185–6  
 medication administration 223  
 memory  
 atrophy and 89  
 cognitive rehabilitation and 178–80  
 fMRI studies 95–6  
 mesenchymal stem cells 72, 73  
 methylprednisolone 4–5, 114, 115, 235  
 mexilitine 33
- microglia  
 activated 14, 15, 16, 24  
 remyelination role of 55  
 sodium channels and 35–6
- mirtazapine 185  
 mitochondria 31  
 mitoxantrone 140  
 moclobemide 185  
 modafinil 115  
 mood and affect disorders  
 anxiety 184  
 bipolar disorder 185–6  
 categorization of 183  
 depression, *see* depression  
 euphoria 186–7  
 pseudobulbar affect (PBA) 187  
 terminology of 183
- motor system  
 fMRI studies 95  
 pre-surgical mapping 106–8
- MS Centers 231–2  
 MS Impact Scale 132  
 MS Impairment Scale 132  
 MS Relapse Management Scale  
 (MSRMS) 235  
 MS Spasticity Scale 132  
 MS Walking Scale 132  
 MS-Specific Fatigue Scale 132  
 Multiple Sclerosis Spasticity Scale  
 (MSSS-88) 167
- myelin basic protein (MBP) 67  
 myelin-associated glycoprotein  
 (MAG) 47  
 myofibroblasts 74  
 myoinositol 88  
 Na<sup>+</sup>/K<sup>+</sup> ATPase 31  
 NAA (*N*-acetyl-aspartate) 10, 12, 81,  
 82, 88  
 nasogastric (NG) tube feeding 224  
 natalizumab 140  
 n-back test 95–6  
 nerve growth factor (NGF) 39  
 neural crest cells (NCC) 68, 70, 71  
 neural crest-derived stem cells  
 (NCSC) 72–3, 74–5  
 neural stem/precursor cells (NPCs)  
 61–2
- inflammation and demyelination  
 62–4  
 regional tropism of associated  
 repair 64  
 role in regeneration/repair in MS 60
- neuregulins 68  
 neurogenesis 13, 60, 61–5  
 neuroplasticity, *see also* cortical  
 reorganization  
 activation after acute lesion 12  
 fMRI studies, *see* functional  
 magnetic resonance imaging  
 (fMRI)  
 pharmacological agents' effect on  
 106  
 redundancy 104  
 sprouting 104  
 stroke studies 103
- neuropsychologist, dysphagia  
 management role 222
- neurotransmitters  
 baclofen's mode of action and 168  
 release of 23, 26  
 spasticity and decrease in 166
- neurotrophins 70  
 nitric oxide 10, 24, 31  
 NMDA (*N*-methyl-D-aspartate) 24  
 NMDA receptors 23  
 nodes of Ranvier 8, 11, 29, 67  
 Noggin 63  
 Nogo-66-receptor (NgR) 47  
 Nogo-A 46, 47–8, 49  
 non-steroidal anti-inflammatory drugs  
 (NSAIDs) 64  
 Nottingham Health Profile 132  
 nucleus ambiguus (NA) 219  
 nucleus tractus solitarii (NTS) 219
- nutrition  
 dysphagia rehabilitation 223–4  
 non-oral route feeding 224
- O2A progenitor cells 53  
 occupational therapy 146, 222  
 olanzapine 186  
 oligoclonal banding 2  
 oligodendrocyte myelin glycoprotein  
 (OMgp) 47  
 oligodendrocyte precursor cells (OPCs)  
 development and properties of  
 human 55–7

- development and properties of rodent 53–4  
nomenclature of 53, 55  
remyelination and 54–5, 57, 61  
Schwann cell (SC) differentiation and 74  
transplantation of 45, 55, 56–7
- oligodendrocytes  
as remyelination requisite 45  
differences from Schwann cells (SC) 67–8
- optic neuritis  
evoked potentials (EPs) studies 112–13, 114  
fMRI studies 94, 95
- orgasmic dysfunction 215, 216
- outcome measures 130–1  
ataxia rehabilitation 210–11  
current and future approach considerations 134–6  
rehabilitation trials 152, 159  
selecting appropriate 131–4
- oxybutynin 192
- Paced Auditory Serial Addition Test (PASAT) 95
- Paced Visual Serial Addition Task (PVSAT) 95
- pelvic floor training 146
- Penn Spasms Scale 167
- percutaneous endoscopic gastrostomy (PEG) tube feeding 224
- perfusion MRI 83
- periaqueductal gray (PAG) 1, 2
- peripheral nerve blockage 171, 169
- phenol 169, 171
- phenytoin 33–5, 36
- phosphocreatine (Cr) 81, 82
- physical therapy/physiotherapy 144–5  
aerobic training comparison 145  
dysphagia management 222  
research findings 159–61, 234  
spasticity treatment 168, 172
- physiopathology (of MS)  
demyelination and axonal loss functional effects 8  
different types of MS 8–9  
diffuse white and gray matter damage 13–16  
lesion-related nervous damage 9–13, 16
- Physiotherapy Evidence Database (PEDro) scale 159
- platelet derived growth factor (PDGF) 53, 55
- platelet-derived growth factor  $\alpha$  receptor (PDGF $\alpha$ R) 53
- pneumonia 220
- pontine micturition center (PMC) 190–1
- positron emission tomography (PET) studies  
sexual dysfunction 216  
stroke 104–5
- posturography 210–11
- potassium channel blockers 100
- pre-surgical mapping 103, 106–8, 108–9
- primary progressive multiple sclerosis (PPMS) characteristics 9
- procaine 33
- progabide 170
- prognosis  
evoked potential (EP) studies 1–2, 112  
lesion-related nervous damage and 9
- proteoglycans 47
- proton MR spectroscopy ( $^1\text{H}$ -MRS)  
gray matter (GM) damage studies 88, 89  
white matter (WM) damage studies 80, 81, 82
- pseudobulbar affect (PBA) 187
- psychotherapy 146, 185
- Purkinje neurons 37–40
- pyramidal dysfunction 4, 5
- Pzero myelin protein (P0) 67
- quality of life  
caregiver's 236  
determinants of 230  
home-based care and 233–4  
outcome measures 132
- Queen Square Stimulator 146
- quetiapine 186
- quinidine 187
- Rasch measurement 135
- recovery mechanisms  
axonal regeneration 45–8  
recession of pathophysiological processes 44  
remyelination 44–5  
reorganization and neuronal plasticity 48–9  
sodium channel density and 30
- stem cell transplantation and 45  
types of 12–13
- regeneration (of CNS)  
brain repair system 60  
in MS 60–1
- Regurin (trospium chloride) 192
- rehabilitation  
adaptation and 153  
ataxia and imbalance 203, 207–11  
cognitive, *see* cognitive rehabilitation  
dysphagia 223–4  
evaluation of 127, 130–6, 141, 147, 154  
extended program of 234  
factors influencing outcome of 143  
home-based programs 231  
mode of action in MS 143  
MS Centers 231–2  
overview of 230–1  
philosophy and principles of 127–31, 141  
problems and limitations of 147–8  
research findings 143–7, 152–4, 159–61, 234–5  
research problems 152, 158–9, 161–2, 209  
role in MS 127  
service delivery modes 142–3  
sexual dysfunction 217  
summary of phases and pitfalls 155  
timing during disease course 142  
value of multidisciplinary approach 143–4, 161  
value of specific treatment modalities 144–7, 159–61
- relapse management 235
- relapsing–remitting MS (RRMS)  
characteristics of 8  
early MRI findings 9
- remyelination  
background to experimental therapeutic approaches 44–5  
causes of failure of 61  
extent of 60–1, 64  
oligodendrocyte precursor cells (OPCs) and 54–5, 57  
Schwann cells (SC) and 67–75  
stem cell transplantation strategies 45
- reserve capacity, concept of 49
- resiniferatoxin (RTX) 7
- resistance training 145, 153
- respiratory impairment 227–8  
interdependence with speech and swallowing 219

## Index

- respiratory impairment (*cont.*)  
 respiratory training for 146, 227  
 treatment in dysarthria 227
- risperidone 186
- rivastigmine 100, 123
- robot-assisted gait training 145
- saltatory conduction 8, 29, 67
- Satisfaction with Performance  
 Questionnaire 130
- Schwann cells (SC)  
 adult sources of 71–3  
 advantages and limitations of CNS  
 grafting of committed 68–70  
 CNS neural precursors 73–4  
 differences from oligodendrocytes  
 67–8  
 embryonic sources of 70–1  
 environmental modification 70  
 future research directions 74–5  
 intrinsic properties modification 70  
 plasticity in PNS development and  
 repair 68
- secondary progressive MS (SPMS)  
 characteristics 9
- selective serotonin reuptake  
 inhibitors (SSRIs) 106, 185,  
 187, 217
- Self Assessment of Occupational  
 Functioning (SAOF) 130
- Self-Identified Goals Assessment  
 (SIGA) 130
- semaphorins 47
- sensory disturbances 215, 217
- Sensory Organization Test (SOT)  
 206, 210
- sexual dysfunction  
 antidepressant drugs and 185  
 female problems 215  
 incidence of 215  
 male problems 215–16  
 neurophysiology 216  
 rehabilitation 217  
 treatment 217
- Shaker exercise 224
- Short Form Health Survey (SF-36)  
 132, 134, 135, 152, 233
- Sickness Impact Profile 132
- sildenafil 217
- simultaneous EEG and fMRI (SEM) 109
- skin derived precursors (SKP) 72–3
- sodium channel blockers 33–6, 37, 40
- sodium channels  
 distribution in myelinated axons 29  
 immune modulation and 35–6  
 isoform expression along  
 myelinated and demyelinated  
 axons 31  
 Nav1.2 and Nav1.6 in EAE 31–2  
 Nav1.2 and Nav1.6 in MS 32–5  
 Nav1.8 in cerebellum in  
 MS 36–40  
 plasticity in demyelinated axons  
 29–30  
 saltatory conduction and 8  
 therapeutic target role of 30–1  
 unrestrained influx and energy  
 insufficiency 31
- sodium/potassium pump  
 (Na<sup>+</sup>/K<sup>+</sup> ATPase) 31
- sodium–calcium exchanger (NCX)  
 30, 32
- solifenacin 4
- Sonic hedgehog (Shh) 53, 68
- Sox10, 73, 74
- spasticity  
 definition of 165  
 epidemiological aspects of 165  
 management approaches 167–8, 172  
 measurement of 166–7  
 outcome measures 132  
 palliative surgery 171  
 pathophysiology of 165–6  
 pharmacological therapy 168–71, 172  
 physical therapy 168, 172  
 sexual dysfunction and 216
- speech and language therapy  
 146, 222, 223
- speech disturbances, *see* dysarthria
- spinal cord  
 atrophy 10, 14  
 fMRI studies 96–7  
 gray matter imaging 89  
 regeneration following injury 62
- stem cells  
 mesenchymal 72, 73  
 neural crest-derived (NCSC) 72–3,  
 74–5  
 neural stem/precursor cells (NPCs)  
*see* neural stem/precursor cells  
 (NPCs)  
 oligodendrocyte precursor cells  
 (OPCs) *see* oligodendrocyte  
 precursor cells (OPCs)  
 skin derived precursors (SKP) 72–3
- steroid therapy  
 evoked potentials for monitoring 1  
 home-based administration 235  
 mania and 185  
 methylprednisolone 4–5, 114,  
 115, 235
- stroke  
 CNS regeneration following  
 experimental acute 62  
 fMRI studies 103–6  
 home-based care studies 232  
 positron emission tomography  
 (PET) studies 104–5  
 prevalence of 103
- Stroop task 96, 100, 123
- sub-granular zone (SGZ) 61–3
- sub-ventricular zone (SVZ) 61–3
- suicide 184, 185
- swallowing disturbances,  
*see* dysphagia
- SWAL-QOL 221
- synapses  
 activation and potentiation of  
 functionally silent  
 connections 13  
 changes in MS 24–5  
 current understanding and future  
 directions 22  
 in vivo assay techniques 25–7  
 synaptic homeostasis/scaling 25  
 synaptic plasticity 22–4, 48  
 synaptogenesis 13, 23–4, 48
- T cells 9, 15, 16
- Tello, F. 60
- telomerase activity 54
- temperature vulnerability  
 (Uhthoff phenomenon)  
 central motor conduction time  
 (CMCT) and 2, 5  
 cooling therapy 146  
 physical activity and 148  
 TST amplitude ratio and 5
- tetrodotoxin (TTX) 30, 31, 33,  
 36, 37
- tizanidine 168, 169
- tolterodine 192
- tractography (diffusion tensor)  
 structural MR damage and  
 functional cortical reorganization  
 studies 98  
 white matter (WM) damage  
 studies 82–3

Cambridge University Press

978-0-521-88832-5 - Multiple Sclerosis: Recovery of Function and Neurorehabilitation

Edited by Jurg Kesselring, Giancarlo Comi and Alan J. Thompson

Index

[More information](#)

## Index

- transcranial magnetic stimulation  
 (TMS) 3, 106, 113  
 fMRI combined with 123  
 triple stimulation technique (TST)  
 3–6, 113
- treadmill training 145, 153
- tremor 40, 201, 203
- tricyclic antidepressants 185, 187
- triple stimulation technique (TST)  
 3–6, 113
- trospium chloride 192
- tumor necrosis factor 10
- Uhthoff phenomenon,  
*see* temperature vulnerability  
 (Uhthoff phenomenon)
- urinary catheterization  
 clean intermittent self (CISC)  
 192–5  
 long-term indwelling 197–8
- urological damage, risk of 194–5
- vaginal dryness 215, 217
- valproic acid 186
- veratridine 38
- Vesicare 4
- videofluoroscopy (VFS) 221
- vigabatrin 170
- vimentin 36
- viruses 8
- vision  
 optic neuritis, *see* optic  
 neuritis  
 recovery of visual acuity 30  
 visual preference  
 205–6, 209
- Wartenberg pendulum test 167
- white matter (WM) damage  
 conventional MRI (cMRI) studies  
 79–80  
 diffuse damage as  
 pathophysiological mechanism  
 13–16  
 novel MR-based studies 82–3  
 structural MR-based studies 80–2
- Wnt signals 53